Biotechnology

As its CEO heads to a top investor conference, Zealand Pharma leverages AI and novel peptides to challenge giants in the multi-billion-dollar obesity market.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A small startup just raised $4M to solve the biggest problem in tech: making AR glasses affordable. Their secret isn't a new gadget, but a materials science breakthrough.

A new study reveals an 'early warning system' in infant guts, offering a window to combat the atopic march before allergies take hold. Is this the future?

As psychedelics go mainstream, a new initiative asks a hard question: what about those most harmed by their prohibition? MAPS' latest project is a radical rethink.

Cell therapies promise miracles, but a decades-old test for cell health is flawed. A new global standard aims to bring much-needed precision and safety.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

Montara Therapeutics' new MJFF grant isn't just about Parkinson's. It's a bet on a 'BrainOnly' platform that could unlock a new era for CNS therapies.

With a fresh $31M, Advanced NanoTherapies is advancing a first-of-its-kind dual-drug nanoparticle balloon, a technology poised to disrupt the market.

As one major allergy drug exits, a biotech startup is testing a new path: a microneedle skin stamp. Is this the future of allergy treatment?

Quoin Pharmaceuticals files the first-ever drug application for Peeling Skin Syndrome, offering a glimmer of hope for patients with no treatment options.

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

Medscape's new AI symposium aims to guide hematologists through an ethical revolution, promising to enhance, not replace, clinical expertise. Is this the future?

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

A novel probiotic, sourced from an elite athlete's gut, has navigated the FDA's complex regulatory maze, signaling a major shift for the entire industry.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

A new partnership is democratizing science for wellness brands, making it faster and cheaper to prove their final products work and earn customer trust.